Technical Analysis for TRDA - Entrada Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 14.49 | 2.11% | 0.30 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 200 DMA Resistance | Bearish | 2.11% | |
| Upper Bollinger Band Walk | Strength | 2.11% | |
| Inside Day | Range Contraction | 2.11% | |
| Gapped Up | Strength | 2.11% | |
| Overbought Stochastic | Strength | 2.11% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| 200 DMA Support | about 13 hours ago |
| 200 DMA Resistance | about 13 hours ago |
| Possible NR7 | about 13 hours ago |
| Possible Inside Day | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/10/2024
Entrada Therapeutics, Inc. Description
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Myotonic Dystrophy Genetic Genealogy Neuromuscular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.44 |
| 52 Week Low | 10.8254 |
| Average Volume | 72,362 |
| 200-Day Moving Average | 14.44 |
| 50-Day Moving Average | 13.14 |
| 20-Day Moving Average | 13.22 |
| 10-Day Moving Average | 13.96 |
| Average True Range | 0.76 |
| RSI (14) | 61.98 |
| ADX | 22.96 |
| +DI | 22.34 |
| -DI | 9.85 |
| Chandelier Exit (Long, 3 ATRs) | 12.58 |
| Chandelier Exit (Short, 3 ATRs) | 14.09 |
| Upper Bollinger Bands | 14.93 |
| Lower Bollinger Band | 11.50 |
| Percent B (%b) | 0.87 |
| BandWidth | 25.96 |
| MACD Line | 0.35 |
| MACD Signal Line | 0.18 |
| MACD Histogram | 0.1717 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.11 | ||||
| Resistance 3 (R3) | 15.14 | 14.98 | 15.00 | ||
| Resistance 2 (R2) | 14.98 | 14.82 | 14.96 | 14.97 | |
| Resistance 1 (R1) | 14.73 | 14.72 | 14.86 | 14.70 | 14.93 |
| Pivot Point | 14.57 | 14.57 | 14.63 | 14.55 | 14.57 |
| Support 1 (S1) | 14.32 | 14.41 | 14.45 | 14.29 | 14.05 |
| Support 2 (S2) | 14.16 | 14.31 | 14.14 | 14.01 | |
| Support 3 (S3) | 13.91 | 14.16 | 13.98 | ||
| Support 4 (S4) | 13.88 |
